Steven J. Rice - 01 Jun 2023 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Signature
/s/ Sung Lee, Attorney-in-Fact
Issuer symbol
VIR
Transactions as of
01 Jun 2023
Net transactions value
-$64,175
Form type
4
Filing time
02 Jun 2023, 12:20:28 UTC
Previous filing
24 Feb 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Sale $64,175 -2,500 -2.3% $25.67 106,840 01 Jun 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2023.
F2 Includes 926 shares of common stock acquired by the reporting person on May 31, 2023 pursuant to an employee stock purchase program.